---
document_datetime: 2023-09-21 21:17:41
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/incresync-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: incresync-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 23.3863197
conversion_datetime: 2025-12-31 04:42:49.085418
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Incresync

Procedural steps taken and scientificinformation after the authorisation

| Application number   | Scope                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amended on   | Product Information affected3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| N/0043               | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                          | 07/09/2022                          |                                           | PL                              |           |
| WS/2191              | Thiswasanapplicationforavariationfollowinga worksharingprocedure accordingtoArticle20of CommissionRequlation(EC)No1234/2008. | 10/06/2022                          | n/a                                       |                                 | n/a       |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| SubmissionofaconsolidatedRMPversion11.1for Vipidia,VipdometandIncresyncin orderto: -Update the RMPsfor Alogliptin, Alogliptin/Pioglitazone fixed dose combination(FDC) andAlogliptin/Metforminfixed dosecombination (FDC)toconsolidatewithinasingleRMPas committedwithinthePSuRprocedure (PSUSA/00010061/202104). -Followingreviewofcumulativesafetydata, removalofanumberofsafetyconcernsisdone basedonGVPModuleV,RiskManagementSystems (revision 2) guidelines. -RemovethetargetfollowupQuestionnairesof SevereHypersensitivityand skinreactions, Pancreatitis, Hepatic events and follow up gastrointestinal events and infections from Alogliptin andAlo/MetRMPs. -Reflecttheremovaloftheinvertedblacktriangleas agreedaspartofthealogliptinrenewalprocedure (EMEA/H/C/002178/R/0023)forAlogliptinandthe FDCAlogliptin/Metformin.Theblacktriangle was alreadyremovedfromtheFDCAlogliptin/Pioglitazone RMPaspartoftheTypeⅡIvariation (EMEA/H/C/002178/I/0029). C.I.11.b -Introductionof,or change(s) to,the obligations andconditionsofa marketing authorisation,includingtheRMp-Implementationof change(s)whichrequiretobefurthersubstantiated bynewadditional datatobesubmittedbytheMAH   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IG/1486/G           | This was an applicationfora group of variations. B.I.a.3.b-Change in batch size(including batch size ranges)ofAsorintermediate-Downscaling downto 10-fold A.4-Administrativechange-Changein thename and/oraddressofamanufactureroranAsMFholder orsupplieroftheAs，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient   | 13/04/2022   | n/a        |                                |                                |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------------------|--------------------------------|
| N/0039              | Minorchangeinlabellingorpackageleafletnot connected with the SPC (Art.61.3 Notification)                                                                                                                                                                                                                                                                              | 25/11/2021   | 04/04/2022 | PL                             |                                |
| PSUSA/10061 /202104 | PeriodicSafetyUpdateEu Singleassessment- alogliptin, alogliptin/ metformin, alogliptin/ pioglitazone                                                                                                                                                                                                                                                                  | 28/10/2021   | n/a        |                                | PRACRecommendation-maintenance |
| WS/1967/G           | Thiswasanapplicationforagroupofvariations followingaworksharingprocedure accordingto Article 20of CommissionRegulation(EC) No 1234/2008. C.I.z -Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation A.1-Administrativechange-Changein the name and/oraddressoftheMAH                                                                      | 18/03/2021   | 04/04/2022 | SmPC,Annex I, Labelling and PL |                                |
| WS/1966             | This was an applicationforavariationfollowing a worksharinqprocedureaccordinqtoArticle20of                                                                                                                                                                                                                                                                            | 14/01/2021   | n/a        |                                |                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | CommissionRegulation(EC)No1234/2008. B.I.a.4.c-Changetoin-processtestsorlimits appliedduringthemanufactureoftheAS-Deletion ofanon-significantin-processtest                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                              |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10061 /202004 | PeriodicSafetyUpdate Eu Singleassessment- alogliptin,alogliptin/metformin,alogliptin/ pioglitazone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12/11/2020 | 07/01/2021 | SmPC and PL | RefertoScientificconclusionsandgroundsrecommending thevariationtotermsoftheMarketingAuthorisation(s)'for PSUSA/10061/202004. |
| IB/0036/G           | Thiswasanapplicationforagroupofvariations. B.Il.e.6.b-Changeinanypartofthe(primary) packaging material not in contact with the finished productformulation-Changethatdoesnotaffect theproductinformation B.ll.d.2.a-Change in testprocedureforthe finished product-Minorchangesto anapprovedtest procedure B.ll.b.5.c-Change to in-processtests orlimits appliedduring themanufactureofthefinished product- Deletion ofa non-significant in-process test B.lL.b.5.b-Change toin-processtestsorlimits appliedduringthemanufactureofthefinished product-Additionofanewtest(s) and limits B.ll.b.3.a-Changeinthemanufacturingprocessof thefinishedorintermediateproduct-Minorchange inthemanufacturingprocess B.lL.b.2.a-Change toimporter,batchrelease arrangements andqualitycontroltestingoftheFP- | 22/12/2020 | n/a        |             |                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | control/testingtakesplace B.lL.b.1.e-Replacementoradditionofa manufacturing sitefortheFp-Sitewhere any manufacturing operation(s)take place,except batch- release,batch control, primary and secondary packaging,fornon-sterilemedicinalproducts                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        |           |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| IB/0034 | C.I.7.b-Deletion of-a strength                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/10/2020 | 07/01/2021 | SmPC, Labelling and PL |           |
|         | This was an applicationfora group of variations. B.Il.b.1.e-Replacementoradditionofa manufacturing sitefortheFp-Sitewhere any manufacturing operation(s)takeplace,exceptbatch- release,batchcontrol,primary andsecondary packaging,fornon-sterilemedicinalproducts B.lL.b.2.a-Change toimporter,batchrelease arrangements andqualitycontroltestingoftheFP- Replacement/additionofa sitewherebatch control/testingtakesplace B.Il.b.3.a-Changeinthemanufacturingprocessof the finished orintermediate product - Minor change in themanufacturingprocess B.lL.b.5.b-Change to in-process tests or limits appliedduringthemanufactureofthefinished product - Addition of a new test(s) and limits B.Il.b.5.c-Changetoin-processtestsorlimits applied during the manufacture of the finished product-Deletionofanon-significantin-processtest B.ll.d.2.a-Chanqe in testprocedurefor the finished | 15/07/2020 | n/a        |                        | IB/0031/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | product- Minor changesto an approved test procedure B.lL.e.6.b-Change in any part ofthe(primary) packagingmaterialnotincontactwiththefinished productformulation-Change thatdoesnot affect theproductinformation                                                                               |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0029 | RMP (version10.1)updates C.I.11.b -Introductionof, or change(s) to,the obligations and conditions ofa marketing authorisation,includingtheRMp-Implementationof change(s)which require tobefurther substantiated bynewadditional datatobesubmittedbytheMAH wheresignificantassessmentisrequired | 13/02/2020 | 07/01/2021 | Annex II and PL | Incresync RMP (version 10.1) includesthe following updates: (i) MAH's proposalfor removal of aRMMs and consequently theDrugUtilisationStudyalongwithremovalofrelevant commitment(EMEA/H/C/002182/LEG/009). (ii)RMPupdatedinthenewtemplateinordertoimplement theGVPModuleVRevision2template alongwith revising/removalofthesafetyconcernsassummarised below: Thesafetyconcernsforthealogliptincomponent have been updated. The safety concerns for the pioglitazone component havebeenalignedwiththeconsolidatedPioglitazonefamily RMP(RMPV27.0aspartof the worksharingvariation procedure[EMEA/H/C/XXXX/wS/1680]). Thesafetyconcernsforalogliptin/pioglitazoneFDC havebeenupdated. (ili)TargetedAdverseEvent(AE)Follow-upQuestionnaires relatedtoAEsofseverehypersensitivityskinreactions, hepaticevents,pancreatitis,bladdercancer,bone fractures,andmacularoedemawerealsoremoved. (iv)RMPhas alsobeenupdatedtoreflecttheremoval of theinvertedblacktriangleasagreedaspartofalogliptin renewalprocedure(EMEA/H/C/002182/R/0019). |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     | AnnexIIofthePIhasbeenupdated accordingly,aswell as localrepresentativeforPoland.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------|
| IA/0030             | B.ll.b.2.a-Change toimporter,batchrelease arrangements andqualitycontroltestingoftheFP- Replacement/additionofasitewherebatch control/testingtakesplace                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 06/11/2019 | n/a |                                                                                    |
| PSUSA/10061 /201904 | PeriodicSafetyUpdateEUSingleassessment- alogliptin,alogliptin/metformin,alogliptin/ pioglitazone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 31/10/2019 | n/a | PRACRecommendation-maintenance                                                     |
| IB/0028/G           | Thiswasanapplicationforagroupofvariations. B.ll.b.1.e-Replacementoradditionofa manufacturing siteforthe Fp-Site where any manufacturing operation(s)take place,exceptbatch- release,batchcontrol,primaryandsecondary packaging,fornon-sterilemedicinalproducts B.ll.b.3.a-Change in the manufacturing process of thefinishedorintermediateproduct-Minorchange inthemanufacturingprocess B.Il.b.5.b-Changetoin-processtestsorlimits applied during the manufacture of the finished product- Addition of a new test(s) and limits B.Il.b.5.c-Changetoin-processtestsorlimits appliedduringthemanufactureofthefinished product-Deletionofa non-significantin-processtest B.ll.d.2.a-Change in testprocedurefor the finished product-Minorchangestoanapprovedtest procedure B.lL.e.6.b-Change in any partofthe(primary) | 10/10/2019 | n/a |                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | packaging material not in contact with the finished product formulation - Change that does not affect theproductinformation                                                                                                                                                                                                                                                                                                                                                 |            |     |                                |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| IG/1071/G           | Thiswas an applicationfora groupof variations. B.Ia.1.a-ChangeinthemanufacturerofAsorofa startingmaterial/reagent/intermediateforAs-The proposed manufacturerispart of the same pharmaceuticalgroupasthecurrentlyapproved manufacturer B.I.a.3.a-Changeinbatch size(includingbatchsize ranges)ofASorintermediate-Upto10-fold increasecomparedtotheoriginallyapprovedbatch size B.Ia.3.b-Change inbatch size(includingbatch size ranges)ofAsorintermediate-Downscalingdownto | 28/03/2019 | n/a |                                |
| IB/0025/G           | This wasan applicationfora group of variations. A.7-Administrativechange-Deletionof manufacturingsites B.lll.2.a.1-Change of specification(s)ofa former nonEuPharmacopoeialsubstancetofullycomply with thePh.Eur.orwithanationalpharmacopoeia of a MemberState-AS                                                                                                                                                                                                           | 01/02/2019 | n/a |                                |
| PSUSA/10061 /201804 | PeriodicSafetyUpdateEu Single assessment- alogliptin, alogliptin/ metformin, alogliptin/ pioqlitazone                                                                                                                                                                                                                                                                                                                                                                       | 31/10/2018 | n/a | PRACRecommendation-maintenance |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     | Basedonthereviewofdataonquality,safetyandefficacy,   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------|
| IB/0022             | C.1.11.z -Introduction of, or change(s)to,the obligations and conditions ofa marketing authorisation,includingtheRMp-Othervariation                                                                                                                                                                                                                                                                                                          | 08/01/2018 | n/a |                                                      |
| PSUSA/10061 /201704 | PeriodicSafetyUpdateEu Singleassessment- alogliptin,alogliptin/metformin,alogliptin/ pioglitazone                                                                                                                                                                                                                                                                                                                                            | 26/10/2017 | n/a | PRACRecommendation-maintenance                       |
| WS/1235/G           | This was an applicationfora groupofvariations followinga worksharingprocedure accordingto Article20ofCommissionRegulation(EC)No 1234/2008. B.I.a.1.a-Change in the manufacturerofAS orof a startingmaterial/reagent/intermediateforAs-The proposed manufacturerispart of the same pharmaceuticalgroup asthecurrently approved manufacturer B.Ia.2.a-Changesin themanufacturing process of theAs-Minorchangeinthemanufacturingprocess oftheAS | 14/09/2017 | n/a |                                                      |
| IB/0021/G           | Thiswasanapplicationforagroupof variations.                                                                                                                                                                                                                                                                                                                                                                                                  | 24/08/2017 | n/a |                                                      |

<div style=\"page-break-after: always\"></div>

|                     | theAs-Minorchangeinthemanufacturingprocess oftheAS B.I.a.2.a - Changes in the manufacturing process of theAs-Minorchangeinthemanufacturingprocess ofthe AS B.1.b.2.e-Change in testprocedureforAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition)for the As or a starting material/intermediate                                                                      |            |            |                        |                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| IB/0018/G           | Thiswasanapplicationforagroupofvariations. C.I.3.a -Change(s) in the SPC, Labelling or PL intendedtoimplementtheoutcomeofaprocedure concerningPSuRorPASSortheoutcomeofthe assessmentdoneunderA45/46-Implementationof wordingagreedbythecompetentauthority C.I.3.z -Change(s)in the SPC,Labelling orPL intendedtoimplementtheoutcomeofaprocedure concerningPSURorPASSortheoutcomeofthe assessmentdoneunderA45/46-Othervariation | 11/01/2017 | 20/12/2017 | SmPC, Annex IⅡI and PL |                                |
| PSUSA/10061 /201604 | PeriodicSafetyUpdateEu Single assessment- alogliptin,alogliptin/metformin,alogliptin/ pioglitazone                                                                                                                                                                                                                                                                                                                             | 27/10/2016 | n/a        |                        | PRACRecommendation-maintenance |
| IG/0734/G           | This was an applicationfora group of variations. B.I.a.1.a-Change in the manufacturerofAS orof a startinqmaterial/reaqent/intermediateforAs-The                                                                                                                                                                                                                                                                                | 13/10/2016 | n/a        |                        |                                |

<div style=\"page-break-after: always\"></div>

|         | proposed manufactureris part of the same pharmaceuticalgroup asthecurrentlyapproved manufacturer B.Ia.1.a-Change in the manufacturerofASorof a startingmaterial/reagent/intermediateforAS-The proposed manufactureris part of the same pharmaceuticalgroup asthecurrently approved manufacturer B.I.a.2.a-Changes in the manufacturing process of theAs-Minorchangeinthemanufacturingprocess oftheAS B.I.a.3.a-Changeinbatch size(includingbatchsize ranges)ofASorintermediate-Upto10-fold increasecomparedtotheoriginallyapprovedbatch size   |            |     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0015 | C.I.11.z -Introduction of,or change(s)to,the obligations and conditions ofa marketing authorisation,includingtheRMp-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                             | 28/04/2016 | n/a |
| WS/0940 | Thiswasan applicationforavariationfollowinga worksharingprocedure accordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.I.11.z-Introduction of,or change(s)to,the obligations and conditionsofa marketing authorisation,includingtheRMP-Othervariation                                                                                                                                                                                                                                                                                 | 28/04/2016 | n/a |
| IG/0652 | C.I.8.a-Introductionoforchangestoasummaryof Pharmacovigilancesystem-ChangesinQPPV (includinqcontactdetails)and/orchanqesinthe                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/01/2016 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | PSMF location                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10061 /201504 | PeriodicSafetyUpdateEUSingleassessment- alogliptin,alogliptin/metformin,alogliptin/ pioglitazone                                                                                                                                                                                                                                                                                                       | 06/11/2015 | n/a        |                        | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0011             | B.ll.d.2.a-Changeintestprocedureforthefinished product- Minor changesto an approved test procedure                                                                                                                                                                                                                                                                                                     | 12/06/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10061 /201410 | PeriodicSafetyUpdateEu Singleassessment- alogliptin,alogliptin/metformin,alogliptin/ pioglitazone                                                                                                                                                                                                                                                                                                      | 10/04/2015 | n/a        |                        | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUV/0008           | PeriodicSafetyUpdate                                                                                                                                                                                                                                                                                                                                                                                   | 20/11/2014 | 15/01/2015 | SmPC and PL            | PleaserefertoIncresyncPSuv/o8EPAR:Scientific conclusions andgroundsrecommendingthevariationto the termsofthemarketingauthorisation                                                                                                                                                                                                                                                                                                                                                                               |
| 6000/NI             | A.1-Administrativechange-Changeinthename and/oraddressoftheMAH                                                                                                                                                                                                                                                                                                                                         | 07/11/2014 | 15/01/2015 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| WS/0519             | Thiswas an applicationforavariationfollowing a worksharingprocedure accordingtoArticle20of CommissionRegulation(EC)No1234/2008. The WSAproposed the update of sections4.4,4.8, and5.1oftheSmPCandinordertoreflectthe resultsofstudy402,aphase3b，randomised, double-blind,placebo-controlled,event-driven study, designed to demonstratethatnoexcessriskofa majoradversecardiovascularevent(MAcE)exists | 24/07/2014 | 15/01/2015 | SmPC                   | Resultsfromstudy402,aphase3b,randomised,double- blind,placebo-controlled,event-driven study,which was designedtodemonstratethatnoexcessriskofamajor adverse cardiovascularevent(MAcE) exists following treatmentwithalogliptincomparedwithplacebowhen addedtostandardofcareinadultswith typeIIdiabetes mellitus(T2DM)and acute coronarysyndrome(AcS),are includedin theSmPC.Theprimary endpointofthe study was achieved,demonstrating non-inferiorityofalogliptin comparedwithplacebofortheprimaryMAcEcomposite. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | following treatment with alogliptin compared with placebowhen addedtostandard ofcareinadults withtypeIIdiabetesmellitus(T2DM)andacute coronary syndrome (Acs). TheMAH tookthis opportunitytopropose amendmentstotheRMPinordertoreflectresults fromstudy402andtoupdateitsstructure according to the new European Union(Eu)template for RMPs. C.I.4 -Change(s) in the SPC,LabellingorPL due to newquality,preclinical,clinicalorpharmacovigilance data                                                                                                  |            |            |           | Therefore,ingeneral,alogliptin wasnot associatedwithan increasedriskofcardiovasculardisease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0002    | TheMAHproposed theupdate of sections4.4,4.8, and5.1oftheSmPCandinordertoreflectthe resultsof study305,aphase 3,randomised,double- blind,active-controlled,2-yearstudy,designedto assesstheefficacy andsafetyofalogliptinin combination with metformin compared withglipizide incombinationwithmetformininadultswithT2DM. The Package leaflet has been updated accordingly. TheMAHtookthisopportunitytopropose consequentialamendmentstotheRMP. C.I.4-Change(s)in theSPC,LabellingorPLdue to new quality,preclinical,clinical orpharmacovigilance data | 24/07/2014 | 15/01/2015 | SmPCandPL | Resultsfromstudy305,aphase3,randomised,double- blind,active-controlled,2-yearstudy,designedtoassess theefficacyandsafetyof alogliptinincombination with metformin compared with glipizide in combinationwith metformininadultswithT2DM,areincludedintheSmPC. Treatment with alogliptin as add on to metformin therapy showedsimilarresultsaftertwoyearsoftreatmentto glipizidein combination with metformin treatment.The dose of glipizide usedin this trial was relativelylow. Furthermore,alogliptintherapywasassociatedwithless hypoglycaemicperiodscomparedtoglipizidetreatmentand theweightofthealogliptingroupreducedslightlyasthe weightof the glipizide group increased slightly.There were nospecificsafetyissuesin this trial. |
| PSUV/0005 | PeriodicSafetyUpdate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/06/2014 | n/a        |           | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0007   | C.I.z-Changes(Safety/Efficacy)ofHumanand                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/05/2014 | n/a        |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                              |            |            |           |                                                                                                                                                                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0006  | Updateofsection4.4oftheSmPCinordertoupdate thesafetyinformationon acutepancreatitis.The Package Leaflet is updated accordingly. C.I.z -Changes(Safety/Efficacy)of Human and VeterinaryMedicinal Products-Othervariation | 25/04/2014 | 15/01/2015 | SmPCandPL | Thescopeof thisvariationwastoupdatesection4.4ofthe SmPCtoupdatethesafetyinformationonacute pancreatitis following recommendations ofan Art 5(3) procedureon GLP-1-based therapies andpancreaticsafety. The Package Leaflet is updated accordingly. The benefit/riskbalanceofIncresyncremainsunchanged |
| IG/0401 | C.I.8.a-Introductionoforchangestoasummaryof Pharmacovigilancesystem-ChangesinQPPV (including contactdetails)and/orchangesinthe PSMFlocation                                                                             | 11/02/2014 | n/a        |           |                                                                                                                                                                                                                                                                                                       |